Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCitius Pharmaceuticals Inc

Citius Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.47 USD -0.01 ( 2.21%)
Last update at 2026-11-12T15:47:00Z
VOLUME
39864
Market Cap
15.38M

Momentum Score

…

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.46
Low
0.49
High
52 Week Price Range
0.47
Low
2.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Citius Pharmaceuticals is a specialty pharmaceutical company focused on developing therapeutic products for critical care, anti-infective and oncology-supportive settings with a pipeline of clinical and development-stage candidates targeting hospital and outpatient care. Long-term growth drivers include potential regulatory approvals, commercialization of late-stage assets and strategic collaborations that may benefit revenue and market penetration; investors should monitor milestone delivery and execution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.48
Dividend Yield
-
Revenue TTM
7.11M
Revenue Per Share
0.33
Gross Profit TTM
5.50M
Debt / Equity
0.03
ROE
-81.09%
Net Debt
-2.44M
ROCE
-44.66%
Diluted EPS TTM
-1.75

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -38.68M -38.85M -31.97M -33.06M -23.05M
Minority interest 2.31M 0.29M 0.00M - -
Net income -37.43M -39.14M -32.54M -33.64M -23.13M
Selling general administrative 18.53M 18.25M 21.91M 15.66M 11.29M
Gross profit -0.21M -0.21M -0.19M - -
Reconciled depreciation 0.21M 0.21M 0.19M 0.18M 0.16M
Ebit -38.42M -38.85M -31.97M -33.32M -23.53M
Ebitda -38.20M -38.64M -31.77M -32.88M -23.05M
Depreciation and amortization 0.21M 0.21M 0.19M 0.43M 0.49M
Non operating income net other - - - - 0.49M
Operating income -38.53M -42.00M -36.73M -33.32M -23.53M
Other operating expenses 38.53M 41.99M 36.73M 33.32M 23.53M
Interest expense 0.27M - - 0.25M 0.01M
Tax provision 1.06M 0.58M 0.58M 0.58M -
Interest income 0.11M 0.76M 1.18M 0.25M 0.26M
Net interest income -0.16M 0.76M 1.18M 0.25M 0.25M
Income tax expense 1.06M 0.58M 0.58M 0.58M 0.07M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 38.31M 42.00M 36.73M 33.32M 23.53M
Cost of revenue 0.21M 0.21M 0.19M - -
Total other income expense net -0.16M 3.15M 4.77M 0.25M 0.48M
Net income from continuing ops -39.74M -39.43M -32.54M -33.64M -23.05M
Net income applicable to common shares - - - -33.64M -24.51M
Preferred stock and other adjustments - - - - 1.45M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 130.94M 116.65M 103.61M 114.00M 142.43M
Intangible assets 92.80M 92.80M 59.40M 59.40M 59.40M
Other current assets 1.40M 2.70M 7.89M 2.85M 2.74M
Total liab 53.41M 42.55M 12.18M 10.57M 9.65M
Total stockholder equity 67.55M 70.08M 90.83M 102.83M 132.18M
Deferred long term liab - - - 5.56M 4.99M
Other current liab 30.13M 30.40M 2.63M 3.17M 2.53M
Common stock 0.02M 0.01M 0.16M 0.15M 0.15M
Capital stock 0.02M 0.01M 0.16M 0.15M 0.15M
Retained earnings -238.80M -201.37M -162.23M -129.69M -96.05M
Other liab - - - 5.56M 4.99M
Good will 9.35M 9.35M 9.35M 9.35M 9.35M
Other assets - - - 0.04M 0.04M
Cash 4.25M 3.25M 26.48M 41.71M 70.07M
Total current liabilities 44.91M 35.81M 5.78M 4.53M 3.98M
Net debt -2.44M -2.99M -26.00M -41.03M -69.22M
Short term debt 1.09M 0.48M 0.22M 0.20M 0.18M
Short long term debt 1.00M - - - -
Short long term debt total 1.81M 0.26M 0.48M 0.68M 0.86M
Other stockholder equity 306.34M 271.44M 252.90M 232.37M 228.08M
Property plant equipment - - - 0.00M 0.01M
Total current assets 27.93M 14.22M 34.37M 44.56M 72.81M
Net tangible assets - - - 102.83M 132.18M
Inventory 22.29M 8.27M - - -
Accounts payable 13.69M 4.93M 2.93M 1.17M 1.28M
Noncontrolling interest in consolidated entity - - - 0.60M 0.60M
Common stock total equity - - - 0.15M 0.15M
Retained earnings total equity - - - -129.69M -96.05M
Non currrent assets other 0.04M 0.04M 44.95M 39.97M 0.04M
Non current assets total 103.00M 102.43M 69.24M 69.44M 69.61M
Capital lease obligations 0.81M 0.26M 0.48M 0.68M 0.86M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -5.00M 0.00M 0.00M -40.01M
Change to liabilities - - - 0.53M 0.13M
Total cashflows from investing activities -5.75M -5.00M - - -40.01M
Net borrowings 1.30M 0.00M - - -0.17M
Total cash from financing activities 33.30M 9.97M 13.83M 0.00M 120.47M
Change to operating activities - - - 0.35M -2.14M
Net income -39.74M -39.43M -32.54M -33.64M -23.05M
Change in cash 1.00M -23.23M -15.23M -28.36M 56.21M
Begin period cash flow 3.25M 26.48M 41.71M 70.07M 13.86M
End period cash flow 4.25M 3.25M 26.48M 41.71M 70.07M
Total cash from operating activities -26.55M -28.20M -29.06M -28.36M -24.25M
Issuance of capital stock 32.30M 13.80M 13.80M 0.00M 89.43M
Depreciation 0.21M 0.21M 0.19M 0.18M 0.16M
Other cashflows from investing activities -5.75M -5.00M - - -40.00M
Change to inventory -12.65M -2.13M 0.00M - -
Sale purchase of stock - - - - 120.64M
Other cashflows from financing activities 33.30M -3.83M 0.03M - 31.21M
Change to netincome - - - 4.48M 1.29M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 40.01M
Change receivables - - - - -0.09M
Cash flows other operating - - - 0.27M -2.53M
Cash and cash equivalents changes - - - -28.36M 56.21M
Change in working capital 1.05M -1.69M -4.01M 0.24M -2.72M
Stock based compensation 10.84M 11.84M 6.62M 3.91M 1.45M
Other non cash items 0.03M 0.28M 0.10M 0.38M 0.07M
Free cash flow -26.55M -28.20M -29.06M -28.36M -64.26M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CTXR
Citius Pharmaceuticals Inc		 -0.01
2.21%		 0.47 - 0.32 2.16 0.24 0.83 -2.74
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

11 Commerce Drive, Cranford, NJ, United States, 07016

908 967 6677

https://citiuspharma.com

23

Name Title Year Born
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Sec. 1945
Mr. Myron Z. Holubiak Co-Founder & Exec. Vice Chairman 1947
Mr. Jaime Bartushak Chief Bus. Officer, CFO & Chief Accounting Officer 1968
Dr. Myron S. Czuczman M.D. Exec. VP & Chief Medical Officer 1960
Mr. Gary F. Talarico Exec. VP of Operations 1955
Ms. Ilanit Allen VP of Investor Relations & Corp. Communications NA
Dr. Alan Lader Ph.D. Sr. VP & Head of Clinical Operations and Quality Assurance NA
Mr. Dhananjay G. Wadekar Sr. VP of Bus. Strategy 1954
Mr. Kelly Creighton Ph.D. Exec. VP of Chemistry, Manufacturing & Controls NA
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Secretary 1945

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…